These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 33197078)
1. Safety, pharmacokinetics and pharmacodynamics of SBT-020 in patients with early stage Huntington's disease, a 2-part study. van Diemen MPJ; Hart EP; Abbruscato A; Mead L; van Beelen I; Bergheanu SC; Hameeteman PW; Coppen E; Winder JY; Moerland M; Kan H; van der Grond J; Webb A; Roos RAC; Groeneveld GJ Br J Clin Pharmacol; 2021 May; 87(5):2290-2302. PubMed ID: 33197078 [TBL] [Abstract][Full Text] [Related]
2. Brain Bio-Energetic State Does Not Correlate to Muscle Mitochondrial Function in Huntington's Disease. van Diemen MPJ; Hart EP; Hameeteman PW; Coppen EM; Winder JY; den Heijer J; Moerland M; Kan H; van der Grond J; Webb A; Roos RAC; Groeneveld GJ J Huntingtons Dis; 2020; 9(4):335-344. PubMed ID: 33325391 [TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. Huntington Study Group Reach2HD Investigators Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848 [TBL] [Abstract][Full Text] [Related]
8. An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease. Süssmuth SD; Haider S; Landwehrmeyer GB; Farmer R; Frost C; Tripepi G; Andersen CA; Di Bacco M; Lamanna C; Diodato E; Massai L; Diamanti D; Mori E; Magnoni L; Dreyhaupt J; Schiefele K; Craufurd D; Saft C; Rudzinska M; Ryglewicz D; Orth M; Brzozy S; Baran A; Pollio G; Andre R; Tabrizi SJ; Darpo B; Westerberg G; Br J Clin Pharmacol; 2015 Mar; 79(3):465-76. PubMed ID: 25223731 [TBL] [Abstract][Full Text] [Related]
9. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. de Yebenes JG; Landwehrmeyer B; Squitieri F; Reilmann R; Rosser A; Barker RA; Saft C; Magnet MK; Sword A; Rembratt A; Tedroff J; Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279 [TBL] [Abstract][Full Text] [Related]
10. Huntington's Disease and Mitochondria. Jodeiri Farshbaf M; Ghaedi K Neurotox Res; 2017 Oct; 32(3):518-529. PubMed ID: 28639241 [TBL] [Abstract][Full Text] [Related]
11. Mitochondrial Dysfunction in Huntington's Disease: Pathogenesis and Therapeutic Opportunities. Sharma A; Behl T; Sharma L; Aelya L; Bungau S Curr Drug Targets; 2021; 22(14):1637-1667. PubMed ID: 33655829 [TBL] [Abstract][Full Text] [Related]
12. Structural and functional changes of the visual cortex in early Huntington's disease. Coppen EM; Grond JV; Hafkemeijer A; Barkey Wolf JJH; Roos RAC Hum Brain Mapp; 2018 Dec; 39(12):4776-4786. PubMed ID: 30144208 [TBL] [Abstract][Full Text] [Related]
13. Increased nuclear DNA damage precedes mitochondrial dysfunction in peripheral blood mononuclear cells from Huntington's disease patients. Askeland G; Dosoudilova Z; Rodinova M; Klempir J; Liskova I; Kuśnierczyk A; Bjørås M; Nesse G; Klungland A; Hansikova H; Eide L Sci Rep; 2018 Jun; 8(1):9817. PubMed ID: 29959348 [TBL] [Abstract][Full Text] [Related]
14. Prefrontal executive function associated coupling relates to Huntington's disease stage. Unschuld PG; Liu X; Shanahan M; Margolis RL; Bassett SS; Brandt J; Schretlen DJ; Redgrave GW; Hua J; Hock C; Reading SA; van Zijl PC; Pekar JJ; Ross CA Cortex; 2013; 49(10):2661-73. PubMed ID: 23906595 [TBL] [Abstract][Full Text] [Related]
15. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis. Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J Elife; 2021 Apr; 10():. PubMed ID: 33871358 [TBL] [Abstract][Full Text] [Related]
16. Reduction in mitochondrial DNA copy number in peripheral leukocytes after onset of Huntington's disease. Petersen MH; Budtz-Jørgensen E; Sørensen SA; Nielsen JE; Hjermind LE; Vinther-Jensen T; Nielsen SM; Nørremølle A Mitochondrion; 2014 Jul; 17():14-21. PubMed ID: 24836434 [TBL] [Abstract][Full Text] [Related]
17. Mitochondrial and Redox-Based Therapeutic Strategies in Huntington's Disease. Fão L; Rego AC Antioxid Redox Signal; 2021 Mar; 34(8):650-673. PubMed ID: 32498555 [No Abstract] [Full Text] [Related]
18. Mitochondrial SIRT3 confers neuroprotection in Huntington's disease by regulation of oxidative challenges and mitochondrial dynamics. Naia L; Carmo C; Campesan S; Fão L; Cotton VE; Valero J; Lopes C; Rosenstock TR; Giorgini F; Rego AC Free Radic Biol Med; 2021 Feb; 163():163-179. PubMed ID: 33285261 [TBL] [Abstract][Full Text] [Related]